Target (CBDY) Accumulated Expenses (2013 - 2020)
Target (CBDY) reported Accumulated Expenses of $1.2 million for Q1 2020, little changed quarter-over-quarter from $1.2 million in Q4 2019.
Target (CBDY) Accumulated Expenses (2013 - 2020) Analysis & Trends
Target (CBDY) has 5 years of Accumulated Expenses data on file, last reported at $1.2 million in Q1 2020.
- Accumulated Expenses for Q1 2020 came in at $1.2 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2020 was $1.2 million (changed N/A YoY), and the FY2019 annual result was $1.2 million, changed N/A from the prior year.
- Accumulated Expenses steadied at $1.2 million in Q1 2020 per CBDY's latest filing, from $1.2 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $1.2 million in Q4 2019 and troughed at $287291.0 in Q2 2018.
- A 3-year average of $840717.8 and a median of $941860.0 in 2019 frame the typical range for Accumulated Expenses.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Target | - | - | 191,787.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 1.19 Mn |
| Dec 31, 2019 | 1.19 Mn |
| Sep 30, 2019 | 691,860.00 |
| Jun 30, 2018 | 287,291.00 |
| Jun 30, 2014 | 1,150.00 |
| Mar 31, 2014 | 1,150.00 |
| Dec 31, 2013 | 400.00 |